SCHEMBL1359564

SCHEMBL1359564

CN(C)[C@H]1CCN(C(=O)c2coc3c(C(C)(C)C)cc(-c4ccc[nH]c4=O)cc23)C1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.39
PDK2 Q15119 1/20 0.38
JAK2 O60674 2/20 0.36
JAK1 P23458 2/20 0.36
TYK2 P29597 2/20 0.36
JAK3 P52333 2/20 0.36
PARP1 P09874 1/20 0.36
TNIK Q9UKE5 1/20 0.34
ATR Q13535 3/20 0.34
MALT1 Q9UDY8 1/20 0.33
MCHR1 Q99705 1/20 0.33
ELANE P08246 3/20 0.33
CHEK1 O14757 1/20 0.33
TLR9 Q9NR96 1/20 0.32
TLR8 Q9NR97 1/20 0.32
TLR7 Q9NYK1 1/20 0.32
CYP3A4 P08684 1/20 0.32
AKT2 P31751 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1359468 1.00 MAP4K4 (0.39) MAP4K4PDK2JAK2JAK1TYK2
SCHEMBL1359465 1.00 MAP4K4 (0.39) MAP4K4PDK2JAK2JAK1TYK2
SCHEMBL1359618 0.89 CHEK1 (0.42) PDK2CHEK1TLR9TLR8TLR7
SCHEMBL1358259 0.88 KDM1A (0.37) PARP1CHEK1CYP3A4
SCHEMBL1357846 0.88 HSP90AA1 (0.40) CHEK1CYP3A4
SCHEMBL3144828 0.87 PDK2 (0.36) PDK2PARP1CHEK1CYP3A4
SCHEMBL1360760 0.87 HTR2C (0.36) PDK2CHEK1CYP3A4
SCHEMBL1360205 0.86 KDM1A (0.38) CYP3A4
SCHEMBL3144840 0.86 CHEK1 (0.37) CHEK1TLR9TLR8TLR7CYP3A4
SCHEMBL1360466 0.86 CHEK1 (0.37) CHEK1TLR9TLR8TLR7CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 US claimed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS MAP4K4 2509/4885PDK2 2000/4885JAK2 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.